GlassScriptPhysician profile
Beth A Rankin
NPI 1316085277
$2,748.00
in general payments reported to CMS, 2019-2025
22 companies · $535 in 2025
The $535 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $82.82 · 2022: $661 · 2023: $830 · 2024: $639 · 2025: $535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,909 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,908.96 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $721.28 | 2021-2025 | |
| Amgen INC. | $561.27 | 2022-2025 | Otezla, Otezla |
| Ucb, INC. | $284.91 | 2021-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $143.79 | 2022-2024 | |
| Janssen Biotech, INC. | $134.48 | 2023-2024 | Tremfya, Simponi, Simponi Aria |
| Incyte Corporation | $127.38 | 2021-2023 | Opzelura |
| Lilly USA, LLC | $122.95 | 2022-2025 | Taltz, Ebglyss |
| Dermavant Sciences, INC. | $104.95 | 2022-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $88.33 | 2023-2025 | Ilumya |
| Leo Pharma INC. | $62.74 | 2022-2024 | Adbry |
| Genzyme Corporation | $61.07 | 2023-2025 | |
| Tolmar, INC. | $52.44 | 2025 | Jatenzo, Eligard, Rubraca |
| Stryker Corporation | $49.59 | 2022 | |
| Novartis Pharmaceuticals Corporation | $45.93 | 2022-2024 | |
| Verrica Pharmaceuticals INC. | $40.15 | 2023-2025 | Ycanth |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $28.00 | 2025 | Vtama |
| Biofrontera INC. | $24.93 | 2021 | |
| Arcutis Biotherapeutics, INC. | $22.26 | 2025 | Zoryve |
| Galderma Laboratories, L.P. | $19.93 | 2025 | |
| Fresenius Kabi USA, LLC | $18.45 | 2024 | Idacio |
| Regeneron Healthcare Solutions, INC. | $18.43 | 2023 | Dupixent |
| Paratek Pharmaceuticals, INC. | $14.74 | 2023 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Rankin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.